In terms of structure, the humerus serves as a connection between the scapula and the elbow, where it links to the two lower arm bones. The humerus bone of the upper arm (the arm in anatomy refers only to the top part of the upper limb i.e. between the elbow and the shoulder).
FDA Approval for Denosumab. Use in Cancer. Denosumab is approved to treat: Giant cell tumor of the bone. It is used in adults and in adolescents whose bones have finished growing. This use is approved for the Xgeva brand of denosumab. Denosumab is approved to prevent and treat: Broken bones and other bone problems caused by solid tumors that have metastasized (spread) to bone. This use is approved for the Xgeva brand of denosumab. Osteoporosis in postmenopausal women who have a high risk of breaking bones. This use is approved for the Prolia brand of denosumab. Denosumab is also approved to increase bone mass in patients who are at high risk of breaking bones.
Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8â12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.